Clinical Trial Update: Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 dose-response study evaluating suppression of endogenous glucose production by HDV-Insulin Lispro in individuals with Type 1 diabetes; the trial is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• HDV-Insulin Lispro (HDV-Insulin Lispro)

Snippet

Sponsor: University of California, San Diego | Conditions: Type 1 Diabetes | Phase 1 | Status: NOT_YET_RECRUITING